Hjem › Metastatisk kreft › Oklahoma › Oklahoma City
Kliniske studier for Metastatisk kreft i Oklahoma City, OK
16 studier for Metastatisk kreft søker deltakere på steder i og rundt Oklahoma City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
RekruttererFase 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruttererFase 1
- University of Oklahoma - Health Sciences Center, Oklahoma City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
RekruttererFase 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RekruttererFase 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Stephenson Cancer Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
RekruttererFase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RekruttererObservasjonsstudie
- Mercy Hospital Oklahoma City, Oklahoma City
Circulating Tumor DNA Response In Urothelial Cancer
RekruttererFase 2
- OU Health Stephenson Cancer Center, Oklahoma City
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
RekruttererFase 2
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
RekruttererFase 1
- University of Oklahoma, Oklahoma City
Metastatisk kreft-studier i andre byer
- Houston, TX104 studier
- New York City, NY93 studier
- Nashville, TN70 studier
- Boston, MA63 studier
- Los Angeles, CA57 studier
- St. Louis, MO54 studier
- Arlington, VA53 studier
- Philadelphia, PA46 studier
- Chicago, IL45 studier
- San Antonio, TX44 studier
- Washington, DC43 studier
- Dallas, TX42 studier
Andre studier i Oklahoma City
- Eggstokkreft28 studier
- Ikke-småcellet lungekreft28 studier
- Endometriekreft25 studier
- Kolorektal kreft22 studier
- Prostatakreft21 studier
- Lungekreft19 studier
- Brystkreft17 studier
- Akut myelogen leukemi14 studier
- Kreft (alle typer)14 studier
- Plateepitelcancer i hode og hals13 studier
- Pankreaskreft11 studier
- Blærekreft11 studier
Fra ClinicalTrials.gov, data hentet 7. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.